Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

Trial Profile

Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daridorexant (Primary)
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Sponsors Idorsia Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2019 Status changed from recruiting to active, no longer recruiting.
    • 22 Oct 2019 According to an Idorsia Pharmaceuticals media release, this trial closed screening in October 2019. The study has a 3-month treatment period with a 1-month safety follow-up so, based on this progress, initial results are expected towards mid-2020.
    • 15 Oct 2019 Planned End Date changed from 1 Nov 2019 to 24 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top